P-346 - Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real...

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Geriatric Oncology
Colon Cancer
Rectal Cancer
Presenter E. François
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors E. François1, S. Kim2, D. Smith3, G. Deplanque4, S. Gourgou5, F. Rollot-Trad6, S. Gally1, A. Berthier1, L. Mineur7
  • 1Centre Antoine Lacassagne, Nice/FR
  • 2University Hospital of Besancon, Besançon/FR
  • 3University Hospital, Bordeaux/FR
  • 4Saint-Joseph Hospital Group, Paris/FR
  • 5and Data Center for Cancer Clinical Trials, Montpellier/FR
  • 6Curie Institute, Paris/FR
  • 7Sainte-Catherine Institute, Avignon/FR

Abstract

Introduction

Approximately half of the patients with metastatic colorectal cancer (mCRC) are elderly, but very few studies have specifically assessed this population. A prospective real-world study was conducted in France in a cohort of elderly patients (≥75 years-old) with mCRC treated in daily practice with bevacizumab, in order to improve the knowledge on this population and to contribute in optimizing treatment strategy.

Methods

CASSIOPEE is a prospective, multicenter, French non-interventional oncogeriatric study conducted over 24 months. Patients aged 75 years or older with mCRC and treated in first-line with bevacizumab and chemotherapy were eligible. The primary objective is to describe progression-free survival (PFS). Secondary objectives include the description of patients' characteristics, overall survival (OS), bevacizumab regimen, safety and autonomy criteria. Results of a planned interim analysis on patients' characteristics are presented.

Results

Between March 2012 and June 2014, recruitment objective was completed with 404 patients (pts) included: 52% were men, mean age 80.5 (±3.8) with 44% patients aged < 80, 45% aged between 80 and 85, and 11% aged > 85. Localization of the primitive primary tumor was colon (80%), rectum (20%). One metastatic site was found in 64% patients, 2 metastatic sites in 28% and 7% patients had 3 or 4 metastatic sites; the main metastatic sites were liver (65%), including liver only (37%), liver/lung (15%) or liver/peritoneum (6%), lung (33%), including lung only (11%), peritoneum (24%); at diagnosis 54% had stage IV CRC and 23% had stage III. Median time (Q1-Q3) between initial diagnosis and inclusion was 3.0 months (1.0-15.0).

Regarding the modified 4 items Lawton Instrumental Activities of Daily Living Scale (IADL 4 items), about half of the patients (49.5%) had a score of 0, 29.2%, 10.5%, 7.4% and 3.4% had a score of 1, 2, 3 and 4, respectively.

Balducci frailty criteria resulted in 39.2%, 20.6% and 3.8% patients for the type 1, 2, and 3, respectively and was not known for 36.4% of patients.

Main comorbidities were cardiovascular diseases (66%), diabetes (25%) and neuropsychological disorders (13%).

Conclusion

CASSIOPEE is the first non-interventional real-world oncogeriatric study describing the cohort's characteristics of elderly patients with mCRC, whom 56% are 80 years-old or more, treated by first-line bevacizumab combined with chemotherapy in daily practice. Recruitment objective was met. Efficacy, safety data and autonomy criteria will be provided after one and two years of follow-up.